Drug Approval | July 17, 2025
SMS Lifesciences India receives EIR with VAI status from USFDA for API facility at Kazipally
The receipt of EIR reaffirms the company's commitment to maintaining global quality standards
The receipt of EIR reaffirms the company's commitment to maintaining global quality standards
Capricor’s BLA for Deramiocel received Priority Review in March 2025
Finerenone significantly reduced the combined risk of cardiovascular death and total (first and recurrent) heart failure events,
The program will offer a structured and immersive learning experience for over 20,000 healthcare professionals across more than 10 cities
Celecoxib is a nonsteroidal anti-inflammatory drug
Ukhade brings deep expertise in large-scale infrastructure planning, cross-functional leadership, and project innovation.
Spikevax is now approved for all individuals aged 6 months through 64 years at increased risk for COVID-19 disease
Apotex will also pay US$ 2.5 million upon receipt of final USFDA approval of the ANDA that is the subject of the Collaboration Agreement for Paclitaxel Protein-Bound Particles for Injectable Suspension
Apollo AyurVAID’s product line features clinically proven formulations certified safe by NABL-accredited laboratories for heavy metals, aflatoxins, microbial content
The FDA set a target action date of April 28, 2026, under the Prescription Drug User Fee Act
Subscribe To Our Newsletter & Stay Updated
